Cariprazine

Generic Name
Cariprazine
Brand Names
Vraylar, Reagila
Drug Type
Small Molecule
Chemical Formula
C21H32Cl2N4O
CAS Number
839712-12-8
Unique Ingredient Identifier
F6RJL8B278
Background

Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipo...

Indication

Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depressio...

Associated Conditions
Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
Associated Therapies
-
Clinical Trials
Related News
yahoo.com
·

US FDA approves Bristol Myers' schizophrenia drug

The U.S. FDA approved Bristol Myers Squibb's schizophrenia drug, Cobenfy (KarXT), which reduces symptoms without common side effects, acquired through the $14 billion takeover of Karuna Therapeutics. Expected to generate $2.5 billion in U.S. sales by 2030, it targets cholinergic receptors, unlike traditional dopamine-targeting antipsychotics. Bristol plans to launch the drug in late October at $1,850 per month, with 80% of patients covered by Medicare and Medicaid.
mondaq.com
·

Antitrust And Competition Life Sciences Quarterly Update Q2 2024

2024 sees ongoing FTC scrutiny of life sciences transactions, including Novo's $16.5B Catalent acquisition and AbbVie's $8.7B Cerevel deal. The FTC challenges 'junk' patents in the FDA's Orange Book and releases an interim report on PBMs. The EU Commission opens its first abuse-of-dominance probe related to Zoetis shelving a veterinary therapy. Despite regulatory focus, deals in radiopharmaceuticals and metabolic diseases proceed without notable investigations.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy